Welcome to the Home of your molecular discovery!


New publication (15th of July)

New publication joitly with UTU and JYU. Here, we show how docking results can be re-scored to improve the separation of active ligands from inactive molecules. Work is based on our old software, Panther, which is steadily working big cat.
Kurkinen S, Lätti S, Pentikäinen OT, Postila PA. Getting Docking into Shape Using Negative Image-Based Rescoring. Journal of Chemical Information and Modeling.

Publication (25th of June 2019)

Jointly with the University of Turku and the University of Jyväskylä, we have published a novel fragment-based virtual screening strategy (F-NIB). As an example of its power, we screened a small commercially available database to identify phosphodiesterase 10A inhibitors. This paper was accepted to Wiley's Chemical Biology & Drug Design.

Publication (6th of June 2019)

Jointly with the University of Turku and the University of Jyväskylä , we have published an article about virtual screening. This paper relies on earlier software development. You can download the paper freely (OA) from the publisher's page, and the latest release of Panther-code from MedChem.fi-site.

Life Science Live & HealthBio 2019

15th-16th of May 2019: We participate into Life Science Live and HealthBio 2019 at Turku Fair Center

If you wish to meet as at HealthBio 2019, please, send email to info@aurlide.fi

1st Research contract (27th of February 2019)

We have made our first deal with pharmaceutical company.


Official est, January 25, 2019

Aurlide ltd started its operation.

At your service

We are here to identify your first hit molecules. By using Aurlide's proprietary technology for vHTS, the hit rate for identification of the first-in-class molecule is very high. Thus far, our team has identified first-in-class molecules for 10 target proteins.

We are here to optimize your hits to leads. By using Aurlide's technology for hit-to-lead optimization, the optimization of hit molecules, including core hopping, to novel high affinity ligands can be applied quickly, thus saving both time and money in progress to clinical phases.

Simultaneous optimization of binding into proteins from human and other wished species. By using Aurlide's discovery platform, it is possible to optimize molecules to bind both to protein in the intended target species and species used in animal tests. This way we can significantly lower the risk for failures at the pre-clinical phase.


E-mail: info@aurlide.fi Turku Finland